UNSPSC 51373320: Aspirin/caffeine/codeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373320 Aspirin/caffeine/codeine is a Commodity code that nominally covers combination analgesic and stimulant medications, but recent state and local procurement activity under this code shows misalignment with the taxonomy — the three posted opportunities involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products, none of which match the specific drug combination the code describes. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited spans emergency response medications (naloxone kits), pharmacy benefit program restructuring and direct manufacturer contracting, and bulk pharmaceutical sourcing through authorized wholesaler networks.

Activity appears concentrated in the Southeast and upper Midwest. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026, with a response deadline of July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription contracting capabilities, designed as preliminary market research before formal RFP development. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted 75 percent on competitiveness and 10 percent on fixed cost for a two-year term effective July 1, 2026. The code shows low volume and mission-misaligned recent activity; the three opportunities suggest this code is either incorrectly applied by issuing bodies or the taxonomy does not reflect current pharmaceutical purchasing patterns in state and local government.